Skip to Main Content

Paper Details

Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Clin Cancer Res
18
2021
BET, BET Bromodomain, BET bromodomain, BET bromodomain protein, BRD4, OTX015, PDX tumor cells, TERT, TERT gene, TERT protein, TERT-Rearranged Neuroblastoma, TERT-rearranged neuroblastoma, TERT-rearranged neuroblastoma cell lines, carfilzomib, mice, mouse, neuroblastoma, patient, patients, transcriptional superenhancers, tumor
Author NameAffiliation
Jamie I FletcherChildren's Cancer Institute
Jamie I FletcherUniversity of New South Wales Sydney
Chelsea MayohChildren's Cancer Institute
Chelsea MayohUniversity of New South Wales Sydney
Pieter MestdaghCenter for Medical Genetics Ghent, Ghent University
Jo VandesompeleCenter for Medical Genetics Ghent, Ghent University
Mark J CowleyChildren's Cancer Institute
Mark J CowleyUniversity of New South Wales Sydney
Glenn M MarshallChildren's Cancer Institute
Glenn M MarshallUniversity of New South Wales Sydney
Glenn M MarshallKids Cancer Centre, Sydney Children's Hospital
Michelle HaberChildren's Cancer Institute
Michelle HaberUniversity of New South Wales Sydney
Matthias FischerUniversity Hospital, University of Cologne
Matthias FischerCenter for Molecular Medicine (CMMC), University of Cologne
Matthias FischerUniversity Hospital, University of Cologne
Matthias FischerCenter for Molecular Medicine (CMMC), University of Cologne
  • 1 - 17

Datasets

Release 1.2